ST红太阳(000525) - 2022 Q1 - 季度财报

Financial Performance - The company's operating revenue for Q1 2022 was CNY 1,528,497,781.36, representing a 77.57% increase compared to CNY 860,778,536.56 in the same period last year[5]. - Net profit attributable to shareholders reached CNY 305,590,608.32, a significant increase of 1,282.89% from CNY 22,097,914.19 year-on-year[5]. - The net profit after deducting non-recurring gains and losses was CNY 314,700,365.59, up 5,074.03% from CNY 6,082,305.44 in the previous year[5]. - Basic and diluted earnings per share were both CNY 0.53, reflecting a 1,225.00% increase from CNY 0.04 in the previous year[5]. - The total comprehensive income for the period attributable to the parent company was CNY 305,590,608.32, an increase of 22,097,914.19 compared to the previous period[29]. Cash Flow - The net cash flow from operating activities was CNY 143,475,487.35, an increase of 124.51% compared to CNY 63,905,357.47 in the same period last year[5]. - Cash inflow from operating activities totaled CNY 1,581,523,644.29, compared to CNY 1,165,406,882.40 in the previous period, representing a significant increase[32]. - Cash outflow from investing activities was CNY 29,156,992.09, compared to CNY 26,019,415.47 in the previous period[33]. - The net cash flow from financing activities was -CNY 100,805,780.36, a decrease from CNY 31,729,501.14 in the previous period[33]. - The company received CNY 287,229,498.62 in borrowings during the period, compared to CNY 294,204,468.00 in the previous period[33]. Assets and Liabilities - Total assets at the end of the reporting period were CNY 9,889,473,247.92, a 1.87% increase from CNY 9,707,619,065.78 at the end of the previous year[5]. - Total liabilities decreased to CNY 8,930,292,382.33 from CNY 9,116,027,372.19, a reduction of approximately 2.0%[25]. - Current assets totaled CNY 4,343,479,362.66, compared to CNY 4,212,848,559.44 at the start of the year, showing a growth of approximately 3.1%[23]. - The company's cash and cash equivalents increased to CNY 279,994,497.00 from CNY 263,435,070.09, representing a growth of about 6.3%[22]. Shareholder Information - Shareholders' equity attributable to the parent company increased by 53.07% to CNY 847,906,422.14 from CNY 553,945,905.99 at the end of the previous year[5]. - The total number of ordinary shareholders at the end of the reporting period was 25,028[15]. - The largest shareholder, Nanjing First Pesticide Group Co., Ltd., held a 31.50% stake, amounting to 182,924,731 shares[15]. Research and Development - Research and development expenses rose significantly by 174.28% to CNY 58,433,681.04 from CNY 21,304,234.40 in the previous year[12]. - The company experienced an increase in research and development expenditures during the reporting period[13]. Operational Changes - The increase in sales during the reporting period was a key driver of revenue growth[13]. - The increase in accounts receivable during the reporting period was the main reason for the financial changes[13]. - The increase in prepaid goods during the reporting period contributed significantly to the financial results[13]. - The company's inventory of goods increased during the reporting period, impacting overall performance[13]. - The company reported a decrease in government subsidies received during the reporting period[13]. Other Transactions - The company transferred 49% equity of Anhui Hongyang Biochemical Co., Ltd. to a fund for approximately RMB 95,556,644.68[17]. - Anhui Ruibang Bio-Tech Co., Ltd. was auctioned off for RMB 214,909,380 due to a financial dispute[18]. Audit Information - The company did not conduct an audit for the first quarter report[34].